Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

Not Recruiting

Trial ID: NCT00352027


The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment.

Official Title

Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin Lymphoma

Stanford Investigator(s)


Inclusion Criteria:

* Patient is less than or equal to 21 years of age
* Patient has a confirmed diagnosis of previously untreated Hodgkin lymphoma
* Has Ann Arbor stage IB, IIIA, or IA/IIA with extranodal extension, multiple nodal involvement (3 or more sites), or bulky mediastinal adenopathy.

Exclusion Criteria:

* Patients with favorable risk features
* Patients with unfavorable risk features
* Patients who have received prior therapy for Hodgkin lymphoma.


procedure: Radiotherapy

drug: Adriamycin®

drug: Vinblastine

drug: Nitrogen Mustard

drug: Cyclophosphamide

drug: Vincristine

drug: Bleomycin

drug: Etoposide

drug: Prednisone

biological: G-CSF

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs

New Trial Alerts